Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23540791 | 0.90 | ALDH1A1 (0.36) | CA14ALDH1A1DPP4MAPTHDAC6 | |
| SCHEMBL1583503 | 0.85 | CA14 (0.37) | CA14CA12CA2CA1HDAC6 | |
| SCHEMBL376299 | 0.84 | F2 (0.38) | CA14ALDH1A1CA12CA2DPP4 | |
| SCHEMBL23624143 | 0.84 | KMT2A (0.40) | CA14ALDH1A1LMNACA12CA2 | |
| SCHEMBL20262979 | 0.84 | CA14 (0.42) | CA14ALDH1A1LMNACA12CA2 | |
| SCHEMBL956549 | 0.84 | ALDH1A1 (0.42) | CA14ALDH1A1LMNADPP4NPSR1 | |
| SCHEMBL10246455 | 0.83 | ALDH1A1 (0.36) | CA14ALDH1A1DPP4MAPTHDAC6 | |
| SCHEMBL490828 | 0.83 | ALDH1A1 (0.36) | CA14ALDH1A1DPP4MAPTHDAC6 | |
| SCHEMBL19271796 | 0.83 | CA14 (0.35) | CA14CA12CA2CA1HDAC6 | |
| SCHEMBL7370203 | 0.82 | ALDH1A1 (0.44) | CA14ALDH1A1LMNACA12CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124214-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2026-05-07 | — | — | US | disclosed |
| US-20250313574-A1 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-10-09 | — | — | US | disclosed |
| EP-4419525-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2025-07-23 | — | — | EP | disclosed |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2025-07-17 | — | — | US | disclosed |
| EP-4536653-A2 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | Eisai R&D Management Co., Ltd. (JP) | 2025-04-16 | — | — | EP | disclosed |
| EP-4419525-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Artios Pharma Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| EP-4419527-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Artios Pharma Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| WO-2024097355-A1 | DEUBIQUITINASE-TARGETING CHIMERAS AND RELATED METHODS | VICINITAS THERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2023239906-A2 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023067353-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-04-27 | — | — | WO | disclosed |
| EP-1066236-A1 | PROCESS FOR HYDROCARBONYLATIONS IN SUPERCRITICAL CARBON DIOXIDE | The Research Foundation of State University of New York (US) | 2001-01-10 | — | — | EP | disclosed |
| WO-2000051993-A2 | DIHETERO-SUBSTITUTED METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2000-09-08 | — | — | WO | disclosed |
| WO-1999050214-A1 | PROCESS FOR HYDROCARBONYLATIONS IN SUPERCRITICAL CARBON DIOXIDE | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1999-10-07 | — | — | WO | disclosed |
| US-5962744-A | USING CATALYST COMPLEX CONTAINING TRANSITION METAL AND PHOSPHITE LIGAND | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1999-10-05 | — | — | US | disclosed |
| EP-0880357-A4 | SYNTHESIS OF CONFORMATIONALLY RESTRICTED AMINO ACIDS, PEPTIDES AND PEPTIDOMIMETICS BY CATALYTIC RING CLOSING METATHESIS | CALIFORNIA INST OF TECHN (US) | 1999-05-12 | — | — | EP | disclosed |
| EP-0880357-A1 | SYNTHESIS OF CONFORMATIONALLY RESTRICTED AMINO ACIDS, PEPTIDES AND PEPTIDOMIMETICS BY CATALYTIC RING CLOSING METATHESIS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1998-12-02 | — | — | EP | disclosed |
| US-5811515-A | SYNTHESIZING PEPTIDE PRECURSOR CONTAINING TWO DOUBLE BONDS, CONTACTING WITH RING CLOSING METATHESIS RUTHENIUM CARBENE COMPLEX CATALYST TO YIELD CONFORMATIONALLY RESTRICTED PEPTIDE | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1998-09-22 | — | — | US | disclosed |
| WO-1997026002-A1 | SYNTHESIS OF CONFORMATIONALLY RESTRICTED AMINO ACIDS, PEPTIDES AND PEPTIDOMIMETICS BY CATALYTIC RING CLOSING METATHESIS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1997-07-24 | — | — | WO | disclosed |
| US-4837349-A | Tertiary-butyldimethylsilyl carbamate derivative and process for producing the same | SUNTORY LIMITED (JP) | 1989-06-06 | — | — | US | disclosed |
| EP-0217243-A2 | Tertiary-butyldimethylsilyl carbamate derivative and process for producing the same | SUNTORY LIMITED (JP) | 1987-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124214-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | CBR1, NR3C1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CA14 825/4885ALDH1A1 1397/4885LMNA 597/4885 |
| US-20250313574-A1 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | NEU1, NEU2, NEU4 | CA14 62/4885ALDH1A1 474/4885LMNA 1117/4885 |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | NQO1, VHL, SDHA | CA14 522/4885ALDH1A1 174/4885LMNA 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.